Serum complement and familial combined hyperlipidemia

Atherosclerosis

Volumn 129, Issue 2, 1997, Pages 271-277

  Ylitalo, Kati ^a   Porkka, Kimmo V K ^a   Meri, Seppo ^a   Nuotio, Ilpo ^b   Suurinkeroinen, Leena ^a   Vakkilainen, Juha ^a   Pajukanta, Päivi ^c   Viikari, Jorma S A ^b   Peltonen, Leena ^c   Ehnholm, Christian ^c   Taskinen, Marja Riitta ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

acylation stimulating protein; adipsin acylation stimulating protein; C3a desArg; complement system; familial combined hyperlipidemia

Indexed keywords

APOLIPOPROTEIN;

ADIPOCYTE; ADULT; ARTICLE; COMPLEMENT SYSTEM; FEMALE; GLUCOSE METABOLISM; HEREDITY; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADIPOCYTES; ADULT; ALCOHOL DRINKING; BLOOD PROTEINS; BODY MASS INDEX; COMPLEMENT C3; COMPLEMENT C3A; COMPLEMENT C4; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; FEMALE; GLUCOSE TOLERANCE TEST; GONADAL STEROID HORMONES; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; SEX FACTORS; SMOKING;

EID: 0030985691     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)06054-6     Document Type: Article

References (26)

1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544.
2. Nikkilä EA, Aro A. Family study of serum lipids and lipoproteins in coronary heart disease. Lancet 1973;1:954.
3. Rose HG, Kranz P, Weinstock M, Juliano J, Haft JI. Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. Am J Med 1973;54:148.
4. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025.
5. Castro Cabezas M, de Bruin TW, Kock LA, Kortlandt W, Van Linde-Sibenius Trip M, Jansen H, Erkelens DW. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metab Clin Exp 1993;42:497.
6. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem-Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993;92:160.
7. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147.
8. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apo B overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 1993;13:1110.
9. Niculescu F, Rus HG, Vlaicu R. Activation of the human terminal complement pathway in atherosclerosis. Clin Immunol Immunopathol 1987;45:147.
10. Seifert PS, Hugo F, Tranum-Jensen J, Zahringer U, Muhly M, Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990;172:547.
11. Muscari A, Bozzoli C, Gerratana C, Zaca F, Rovinetti C, Zauli D, La Placa M, Puddu P. Association of serum IgA and C4 with severe atherosclerosis. Atherosclerosis 1988;74:179.
12. Muscari A, Bozzoli C, Puddu GM, Rovinetti C, Fiorentini GP, Roversi RA, Puddu P. Correlations between serum lipids and complement components in adults without demonstrated atherosclerotic disease. Atherosclerosis 1990;81:111.
13. Baldo A, Sniderman AD, St-Luce S, Avramoglu RK, Maslowska M, Hoang B, Monge JC, Bell A, Mulay S, Cianflone K. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest 1993;92:1543.
14. Röschlau von P, Bernt E, Gruber W. Enzymatische Bestimmung des Gesamt-Cholesterins im Serum. Z Kli Chem Klin Biochem 1974;12:403.
15. Wahlefeld AW. Triglycerides: determination after enzymatic hydrolysis. In: Bergmeyer HV, ed. Methods of enzymatic analysis, New York: Verlag Chemie/Academic Press, 1974;1831.
16. Miles J, Glasscock R, Aikens J, Gerich J, Haymond M. A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res 1983;24:96.
17. Norusis MJ. SPSS for Windows: Base system users guide, release 5.0, Chicago, IL: SPSS Inc., 1992;671.
18. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230.
19. Bookstein L, Gidding SS, Donovan M, Smith FA. Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Arch Intern Med 1990;150:1653.
20. Muscari A, Bozzoli C, Puddu G, Sangiorgi Z, Dormi A, Rovinetti C, Descovich GC, Puddu P. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995;98:357.
21. Cianflone KM, Sniderman AD, Walsh MJ, Vu HT, Gagnon J, Rodriguez MA. Purification and characterization of acylation stimulating protein. J Biol Chem 1989;264:426.
22. Cianflone K, Vu H, Walsh M, Baldo A, Sniderman A. Metabolic response of acylation stimulating protein to an oral fat load. J Lipid Res 1989;30:1727.
23. Kwiterovich P Jr, Motevalli M, Miller M. Acylation-stimulatory activity in hyperapobetalipoproteinemic fibroblasts: enhanced cholesterol esterification with another serum basic protein, BP II. Proc Natl Acad Sci USA 1990;87:8980.
24. Cianflone K, Maslowska M, Sniderman AD. Impaired response in fibroblasts in patients with hyperapobetalipoproteinemia to acylation stimulating protein. J Clin Invest 1990;85:722-730.
25. Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C, Zeng Z, Su K, Jurewicz AJ, Hertzberg RP, Bergsma DJ, Kumar C. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 1996;271:20231-20234.
26. Crass T, Raffetseder U, Martin U, Grove M, Klos A, Köhl J, Bautsch W. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur J Immunol 1996;26:1944-1950.